Merck Frosst Canada, Inc.

Merck Frosst Canada & Co.

Axys Pharmaceuticals, Inc.

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Merck Canada Inc.

Serge Leger

Zhaoyin Wang

Petpiboon Prasit

Michel Therien

Cameron Black

Jacques Yves Gauthier

Yves Leblanc

Yves Ducharme

Erich L Grimm

Michel L Belley

John Howard Hutchinson

Cheuk K Lau

Daniel Guay

Chun Sing Li

Richard Frenette

Patrick Roy

Christophe Mellon

Dan McKay

Vouy-Linh Truong

Robert N Young

Michael J Green

Robert J Zamboni

Rejean Fortin

John W Gillard

Marc Labelle

Bernard Hirschbein

James T Palmer

Christopher I Bayly

Chitra Baskaran

Yi B Xiang

James William Janc

Yongxin Han

Pierre A Hamel

Greg Hughes

Gregory Hughes

Haydn W Williams

Nathalie Ouimet

David Percival

Marc Ouellet

Vouy Linh Truong

Dan Mckay

James W Janc

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Cathepsin cysteine protease inhibitors

The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I:

Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.

Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2

The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).

Diaryl-2-(5H)-furanones as Cox-2 inhibitors

The invention encompasses compounds of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I ##STR1## e.g. (5R)-3-(3,4-difluorophenyl)-5-ethyl-5-methyl-4-[4-(methylsulfonyl)phenyl]- 2,5-dihydro-2-furanone.

Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

(methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2

3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors

The present invention relates to inhibitors of COX-2, compositions which contain such compounds and methods of use. The compounds are represented by formula I: ##STR1## and include pharmaceutically acceptable salts and esters thereof.

Bisaryl COX-2 inhibiting compounds, compositions and methods of use

Alkylated styrenes as prodrugs to COX-2 inhibitors

Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I: ##STR1##

Use of inhibitors of cyclooxygenase in the treatment of

Growing community of inventors

Dollard Des Ormeaux, Canada

Serge Leger